| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
BX430 is a novel, potent, selective allosteric/con-competitive antagonist of human P2X4 receptor channels with an IC50 of 0.54 μM. It has the potential to be used for chronic pain and cardiovascular disease.
| ln Vitro |
P2X1–P2X3, P2X5 and P2X7 are the additional P2X isoforms on which BX430 has minimal functional influence [1]. While BX430 has little effect on junctional and connector P2X4 homologues, it is a powerful single antioxidant against zebrafish P2X4 [1]. Human P2X4-expressing cells treated with thapsigargin plus BX430 demonstrated a large rise in intracellular calcium caused by ATP [1]. In THP-1 cells, BX430 (5 μM) dramatically lowers ATP-induced intracellular calcium []. 1].
|
|---|---|
| References |
| Molecular Formula |
C15H15BR2N3O
|
|---|---|
| Molecular Weight |
413.107
|
| Exact Mass |
410.958
|
| CAS # |
688309-70-8
|
| PubChem CID |
2810999
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
395.4±42.0 °C at 760 mmHg
|
| Flash Point |
192.9±27.9 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.679
|
| LogP |
4.56
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
342
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JFNKIJKRXKPQCC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H15Br2N3O/c1-9(2)10-6-12(16)14(13(17)7-10)20-15(21)19-11-4-3-5-18-8-11/h3-9H,1-2H3,(H2,19,20,21)
|
| Chemical Name |
N-[2,6-Dibromo-4-(1-methylethyl)phenyl]-N'-3-pyridinyl-urea
|
| Synonyms |
BX430 BX-430 BX 430
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~201.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4207 mL | 12.1033 mL | 24.2066 mL | |
| 5 mM | 0.4841 mL | 2.4207 mL | 4.8413 mL | |
| 10 mM | 0.2421 mL | 1.2103 mL | 2.4207 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA